Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer

European Journal of Cancer

Volumn 36, Issue 18, 2000, Pages 2301-2312

  Robain, M ^a   Pierga, J Y ^a   Jouve, M ^a   Asselain, B ^a   Dieras V ^a   Beuzeboc, P ^a   Palangie T ^a   Dorval, T ^a   Extra, J M ^a   Scholl, S ^a   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Chemotherapy; Metastatic breast cancer; Prognostic factors

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LACTATE DEHYDROGENASE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN C; TAMOXIFEN; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; PLEURA METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0033710653     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00325-7     Document Type: Article

References (39)

1. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
2. 2) in FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
3. Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients
4. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?
5. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy
6. Progress in chemotherapy for metastatic breast cancer
7. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
8. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC Breast Group study
9. Response to chemotherapy is the first prognostic factor in metastatic breast cancer
10. Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland
11. Regression models and life tables
12. Nonparametric estimation from incomplete observations
13. Evaluation of survival data and two new rank order statistics arising in its consideration
14. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy
15. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
16. Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer
17. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
18. Effect of adjuvant systemic therapy on response to treatment after relapse
19. P-glycoprotein expression in treated and untreated human breast cancer
20. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy
21. Chemotherapy of advanced breast cancer: Outcome and prognostic factors
22. Clinical course and prognostic factors following bone recurrence from breast cancer
23. Multivariate analysis of prognostic factors in metastatic breast cancer
24. Clinical course of breast cancer patients with liver metastases
25. Construction and validation of a practical prognostic index for patients with metastatic breast cancer
26. Steroid-hormone receptors and survival after first relapse in breast cancer
27. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast
28. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer
29. Survival after recurrence of breast cancer
30. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy
31. Classification of patients with disseminated cancer of the breast
32. Prognostic factors in recurrent breast cancer: Relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading
33. Prognostic factors in the response of a first line chemotherapy in advanced breast cancer
34. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support
35. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy
36. Survival patterns in hormone treated advanced breast cancer
37. Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)
38. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer
39. Anthracycline resistance: The problem and its current definition